Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

3.00USD
4:00pm EDT
Change (% chg)

$-0.04 (-1.32%)
Prev Close
$3.04
Open
$3.03
Day's High
$3.09
Day's Low
$2.99
Volume
61,308
Avg. Vol
172,814
52-wk High
$15.93
52-wk Low
$1.64

BCRX.OQ

Chart for BCRX.OQ

About

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $224.03
Shares Outstanding(Mil.): 73.69
Dividend: --
Yield (%): --

Financials

  BCRX.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -0.69 -- --
ROI: -94.03 -9.20 14.43
ROE: -109.99 -9.24 15.61

BRIEF-BioCryst receives more funding for developing treatment for hemorrhagic fever virus diseases

* Funding represents an additional $5.5 million to BioCryst for development of BCX4430 as a treatment for hemorrhagic fever viruses

Jul 05 2016

BRIEF-Biocryst Q1 loss per share $0.31

* Q1 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S

May 05 2016

BRIEF-Venrock Healthcare Capital reports 7.1 pct passive stake in Biocryst Pharmaceuticals

* Venrock Healthcare Capital Partners, L.P. reports 7.1 percent passive stake in Biocryst Pharmaceuticals, Inc. as of March 16, 2016 - SEC filing Source text http://1.usa.gov/1MwPrzN Further company coverage:

Mar 28 2016

UPDATE 3-BioCryst shares tumble after genetic disorder drug fails study

* Shares fall as much as 68 pct (Adds details, analyst comment, updates shares)

Feb 08 2016

BioCryst's genetic disorder drug fails study, shares slump

Drug developer BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, a rare genetic condition.

Feb 08 2016

BioCryst's lead drug for rare genetic disorder fails study

Feb 8 Drug developer BioCryst Pharmaceuticals Inc said its lead drug for a rare genetic condition had failed in a large trial to reduce the frequency of recurrent swelling in patients.

Feb 08 2016

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,530 -53.00
Eisai Co., Ltd (4523.T) ¥6,203 -98.00
Roche Holding Ltd. (ROG.S) CHF250.30 +1.50
Roche Holding Ltd. (RO.S) CHF251.25 +1.25
GlaxoSmithKline plc (GSK.L) 1,667.00p +10.00
Shire PLC (SHP.L) 4,907.00p +37.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.